Allakos LLC, formerly known as Allakos Inc. is a biotechnology company. The Company is developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 04:00:00 2025-05-14 pm EDT			5-day change	1st Jan Change
0.3291 ^USD	-0.06%		-.--%	-

25-05-15	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
25-05-15	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI

Capitalization	29.74M 25.25M 23.1M 21.86M 40.67M 2.83B 41.04M 274M 107M 1.35B 112M 109M 4.67B	P/E ratio 2023	-1.28x	P/E ratio 2024	-0.93x
Enterprise value	-46.92M -39.83M -36.44M -34.49M -64.16M -4.47B -64.74M -432M -169M -2.13B -176M -172M -7.37B	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	96.57%	Yield 2023 *	-	Yield 2024	-

25-05-15	Allakos Inc. Announces Resignation of Dr. Robert Alexander as CEO	CI
25-05-15	Allakos Inc. Announces Resignation of Baird Radford as CFO	CI
25-05-15	Allakos Inc. Announces Executive Changes	CI
25-05-14	Allakos Inc.(NasdaqGS:ALLK) dropped from NASDAQ Composite Index	CI
25-05-14	Concentra Biosciences, LLC completed the acquisition of Allakos Inc..	CI
25-05-08	Allakos Inc.(NasdaqGS:ALLK) dropped from S&P TMI Index	CI
25-05-07	Allakos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-02	Allakos to Be Acquired by Concentra Biosciences for $0.33 per Share	MT
25-04-02	Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences	RE
25-04-01	Concentra Biosciences, LLC entered into an agreement to acquire Allakos Inc. for $31 million.	CI
25-03-12	Allakos Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
25-03-12	Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	CI
25-01-27	Top Midday Decliners	MT

24-01-17	Barclays Trims Allakos' Price Target to $1 From $1.50, Maintains Underweight Rating	MT
24-01-17	JMP Securities Adjusts Allakos' Price Target to $3 From $10, Maintains Market Outperform Rating	MT
24-01-17	Jefferies Downgrades Allakos to Hold From Buy, Adjusts Price Target to $1.50 From $6	MT
24-01-16	Cantor Fitzgerald Downgrades Allakos to Neutral From Overweight	MT
24-01-16	Lifesci Capital Downgrades Allakos to Market Perform From Outperform	MT

Allakos Inc. Stock

Equities

ALLK

US01671P1003

Biotechnology & Medical Research

Valuation: Allakos Inc.

Chart: Allakos Inc.

Latest news : Allakos Inc.

Analysts' recommendations: Allakos Inc.

Press Releases: Allakos Inc.

News in other languages: Allakos Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Allakos Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

22-07-22	Lonza-Aktien sinken nach Halbjahreszahlen
19-12-05	EN DIRECT DES MARCHES : Kering / Moncler, FDJ, Engie, Capgemini, Cybergun, Amazon, Fiat Chrysler...
19-12-05	Des marchés moins cyclothymiques pour finir la semaine ?

1 year	0.33	0.33
3 years	0.22	5.64
5 years	0.22	112.87
10 years	0.22	157.98

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ALLAKOS INC.	-0.06%	-.--%	+0.18%	-92.33%	29.74M
LONZA GROUP AG	-0.25%	+0.54%	-17.61%	-14.85%	43.39B
BEONE MEDICINES AG	-0.44%	+5.75%	+33.95%	+26.77%	34.7B
REVOLUTION MEDICINES, INC.	+1.65%	+3.35%	+256.63%	+473.62%	30.15B
IQVIA HOLDINGS INC.	-2.89%	+10.00%	+16.48%	-7.73%	29.83B
CELLTRION, INC.	-3.58%	-4.59%	+25.92%	+23.61%	28.46B
ASCENDIS PHARMA A/S	+0.00%	+8.03%	-	-	14.82B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-6.66%	-6.15%	+183.75%	+4,189.75%	14.48B
IONIS PHARMACEUTICALS, INC.	-0.44%	+0.13%	+133.66%	+110.38%	12.51B
EUROFINS SCIENTIFIC SE	-1.38%	-0.85%	+3.87%	-4.66%	12.29B
Average	-1.40%	+2.83%	+70.76%	+522.73%	22.07B
Weighted average by Cap.	-1.28%	+3.37%	+66.85%	+374.04%

	2023	2024
Net sales	-	-
Net income	-186M -158M -144M -136M -254M -17.7B -256M -1.71B -668M -8.42B -697M -682M -29.19B	-116M -98.31M -89.94M -85.13M -158M -11.04B -160M -1.07B -417M -5.25B -435M -425M -18.2B
Net Debt	-129M -110M -100M -95.06M -177M -12.33B -178M -1.19B -465M -5.87B -485M -475M -20.33B	-76.66M -65.07M -59.53M -56.35M -105M -7.31B -106M -706M -276M -3.48B -288M -282M -12.05B